Scholar Rock Holding Corp
A biopharmaceutical company in Cambridge, Massachusetts that develops antibody medicines for muscle-wasting diseases. Its lead therapy, apitegromab, targets a protein that limits muscle growth and is being tested for spinal muscular atrophy. Founded in 2012 by Harvard Medical School researchers, the company takes its name from Chinese "scholar's rocks"—eroded stones prized for sparking insight—because their rugged shapes resemble the protein structures it studies.
Granted 6.8K
Granted 96.6K
Sold 30.6K
Sold 12.2K
Sold 10.2K
Sold 10.4K
Granted 6.8K
Granted 6.8K
Granted 6.8K
Granted 6.8K
Granted 6.8K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Akkaraju SrinivasDirector · 1 transaction | +0.1% | 12.23M | 6.8K | — | — |
| Burow KristinaDirector · 5 transactions | +2.1% | 4.81M | 96.6K | — | — |
| Hallal DavidChief Executive Officer, Director · 1 transaction | -1.6% | 1.84M | — | — | 30.6K |
| Vaishnaw AkshayPresident of R&D, Director · 1 transaction | -1.9% | 630.5K | — | — | 12.2K |
| Woods KeithChief Operating Officer · 1 transaction | -1.6% | 620.1K | — | — | 10.2K |
| Sinha VikasChief Financial Officer · 1 transaction | -1.7% | 619.9K | — | — | 10.4K |
| Gilman MichaelDirector · 1 transaction | +7.1% | 62.1K | 6.8K | — | — |
| Flier Jeffrey S.Director · 1 transaction | +19.4% | 42.0K | 6.8K | — | — |
| Peng KatieDirector · 1 transaction | +20.8% | 39.7K | 6.8K | — | — |
| Reed JoshuaDirector · 1 transaction | +39.1% | 22.6K | 6.8K | — | — |
| Brudnick RichardDirector · 1 transaction | +33% | 21.9K | 6.8K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 6 months: -63.5K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.